> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# AIDS Group Wants Gilead Investigated
- URL: https://www.fdaweb.com/aids-group-wants-gilead-investigated/
- Published: 2016-06-01T12:00:00.000Z
- Updated: 2026-09-14T21:06:43.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5135806

The AIDS Healthcare Foundation (AHF) says that FDA and Congress should investigate AIDS drug manufacturer Gilead Sciences for potential patent manipulation and antitrust violations. AHF says the company demonstrated “bald-faced greed” and “disregard for patient safety” in its development of TAF (tenofovir alafenamide fumarate), which can work at a fraction of the cost of its leading HIV drug Viread, and with fewer side effects.

According to AHF, Gilead scientists had the compound available, and clinical evidence that it could cut toxicity, more than a decade ago. It cites a *Los Angeles Times* report indicating that the company stopped research on TAF in 2004, while Viread went on for most of its patent life and grew to $1.1 billion in 2015 sales, even as some patients suffered serious damage to their kidneys and bones.

AHF, which filed suit against Gilead earlier this year claiming that the company delayed TAF in “a calculated, anticompetitive manner” to keep Viread prices high and prevent generic drug companies from gaining market share, says that the company restarted its TAF research in 2010 and then launched Genvoya 11/2015 in a move to save Gilead’s HIV franchise from blockbuster sale losses when Viread goes off patent in 2018.

In response to the AHF suit, Gilead has said that it “had no duty to develop, test, seek approval of, or launch its new product on any particular timetable.”